
Randomized Trial of Adjuvant Chemotherapy with High-dose Doxorubicin, Ifosfamide and Lenograstim (G-CSF) in High Grade Soft Tissue Sarcoma

Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)

Randomized Trial of Single Agent Doxorubicin Vs. Doxorubicin plus Ifosfamide in First Line Treatment of Advanced or Metastatic Soft Tissue Sarcoma

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Inventory
Show Tissue Samples
Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
SARCOMA | SR3 | 13 | 0 | 0 | 0 |
SARCOMA | SR4 | 49 | 1 | 0 | 1 |
SARCOMA | SR5 | 13 | 9 | 10 | 10 |
SARCOMA | SR6 | 26 | 10 | 20 | 20 |
(Core size is 0.6 mm)
Show
Fluid SamplesDisease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
SARCOMA | SR3 | 13 | 0 | 0 |
SARCOMA | SR4 | 49 | 0 | 0 |
SARCOMA | SR5 | 13 | 0 | 0 |
SARCOMA | SR6 | 26 | 1 | 9 |
Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
SARCOMA | SR3 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SARCOMA | SR4 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SARCOMA | SR5 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SARCOMA | SR6 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |